Focus Advisor Solutions LLC increased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 71.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,488 shares of the biotechnology company’s stock after acquiring an additional 18,885 shares during the quarter. Focus Advisor Solutions LLC’s holdings in Exelixis were worth $2,657,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the company. Parallel Advisors LLC increased its holdings in shares of Exelixis by 2.0% in the third quarter. Parallel Advisors LLC now owns 9,456 shares of the biotechnology company’s stock worth $552,000 after purchasing an additional 186 shares during the period. Private Client Services LLC raised its position in shares of Exelixis by 0.7% in the third quarter. Private Client Services LLC now owns 28,539 shares of the biotechnology company’s stock worth $1,667,000 after buying an additional 209 shares in the last quarter. CENTRAL TRUST Co raised its position in shares of Exelixis by 44.9% in the third quarter. CENTRAL TRUST Co now owns 784 shares of the biotechnology company’s stock worth $46,000 after buying an additional 243 shares in the last quarter. Allworth Financial LP boosted its stake in Exelixis by 2.9% during the third quarter. Allworth Financial LP now owns 10,864 shares of the biotechnology company’s stock valued at $591,000 after buying an additional 302 shares during the period. Finally, Brindle & Bay Financial Advisors LLC boosted its stake in Exelixis by 8.0% during the third quarter. Brindle & Bay Financial Advisors LLC now owns 4,105 shares of the biotechnology company’s stock valued at $240,000 after buying an additional 305 shares during the period. 85.27% of the stock is currently owned by hedge funds and other institutional investors.
Exelixis Stock Performance
EXEL stock opened at $64.63 on Friday. The firm has a market cap of $15.77 billion, a P/E ratio of 19.35, a P/E/G ratio of 1.67 and a beta of 0.45. The firm’s fifty day moving average is $63.20 and its 200 day moving average is $52.84. Exelixis, Inc. has a 52 week low of $39.71 and a 52 week high of $73.69.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on EXEL shares. Royal Bank Of Canada upped their target price on Exelixis from $51.00 to $58.00 and gave the stock a “sector perform” rating in a research note on Friday, October 30th. Citizens Jmp lifted their price target on Exelixis from $55.00 to $65.00 and gave the company a “market outperform” rating in a research report on Monday, October 19th. Truist Financial boosted their price objective on Exelixis from $54.00 to $60.00 and gave the stock a “hold” rating in a report on Friday, October 30th. TD Cowen upped their price objective on shares of Exelixis from $55.00 to $76.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Weiss Ratings upgraded shares of Exelixis from a “buy (a-)” rating to a “buy (a)” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Hold” and an average target price of $58.62.
Check Out Our Latest Report on EXEL
Exelixis Company Profile
Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.
Further Reading
- Five stocks we like better than Exelixis
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
